Cargando…

Population Pharmacogenomics for Health Equity

Health equity means the opportunity for all people and populations to attain optimal health, and it requires intentional efforts to promote fairness in patient treatments and outcomes. Pharmacogenomic variants are genetic differences associated with how patients respond to medications, and their pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Jordan, I. King, Sharma, Shivam, Mariño-Ramírez, Leonardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606908/
https://www.ncbi.nlm.nih.gov/pubmed/37895188
http://dx.doi.org/10.3390/genes14101840
_version_ 1785127428260102144
author Jordan, I. King
Sharma, Shivam
Mariño-Ramírez, Leonardo
author_facet Jordan, I. King
Sharma, Shivam
Mariño-Ramírez, Leonardo
author_sort Jordan, I. King
collection PubMed
description Health equity means the opportunity for all people and populations to attain optimal health, and it requires intentional efforts to promote fairness in patient treatments and outcomes. Pharmacogenomic variants are genetic differences associated with how patients respond to medications, and their presence can inform treatment decisions. In this perspective, we contend that the study of pharmacogenomic variation within and between human populations—population pharmacogenomics—can and should be leveraged in support of health equity. The key observation in support of this contention is that racial and ethnic groups exhibit pronounced differences in the frequencies of numerous pharmacogenomic variants, with direct implications for clinical practice. The use of race and ethnicity to stratify pharmacogenomic risk provides a means to avoid potential harm caused by biases introduced when treatment regimens do not consider genetic differences between population groups, particularly when majority group genetic profiles are assumed to hold for minority groups. We focus on the mitigation of adverse drug reactions as an area where population pharmacogenomics can have a direct and immediate impact on public health.
format Online
Article
Text
id pubmed-10606908
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106069082023-10-28 Population Pharmacogenomics for Health Equity Jordan, I. King Sharma, Shivam Mariño-Ramírez, Leonardo Genes (Basel) Perspective Health equity means the opportunity for all people and populations to attain optimal health, and it requires intentional efforts to promote fairness in patient treatments and outcomes. Pharmacogenomic variants are genetic differences associated with how patients respond to medications, and their presence can inform treatment decisions. In this perspective, we contend that the study of pharmacogenomic variation within and between human populations—population pharmacogenomics—can and should be leveraged in support of health equity. The key observation in support of this contention is that racial and ethnic groups exhibit pronounced differences in the frequencies of numerous pharmacogenomic variants, with direct implications for clinical practice. The use of race and ethnicity to stratify pharmacogenomic risk provides a means to avoid potential harm caused by biases introduced when treatment regimens do not consider genetic differences between population groups, particularly when majority group genetic profiles are assumed to hold for minority groups. We focus on the mitigation of adverse drug reactions as an area where population pharmacogenomics can have a direct and immediate impact on public health. MDPI 2023-09-22 /pmc/articles/PMC10606908/ /pubmed/37895188 http://dx.doi.org/10.3390/genes14101840 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Jordan, I. King
Sharma, Shivam
Mariño-Ramírez, Leonardo
Population Pharmacogenomics for Health Equity
title Population Pharmacogenomics for Health Equity
title_full Population Pharmacogenomics for Health Equity
title_fullStr Population Pharmacogenomics for Health Equity
title_full_unstemmed Population Pharmacogenomics for Health Equity
title_short Population Pharmacogenomics for Health Equity
title_sort population pharmacogenomics for health equity
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606908/
https://www.ncbi.nlm.nih.gov/pubmed/37895188
http://dx.doi.org/10.3390/genes14101840
work_keys_str_mv AT jordaniking populationpharmacogenomicsforhealthequity
AT sharmashivam populationpharmacogenomicsforhealthequity
AT marinoramirezleonardo populationpharmacogenomicsforhealthequity